OKYO Pharma opened lower at $1.39, compared with its previous close of $1.42. In the last trading session, the stock traded between $1.33 and $1.42. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in OKYO Pharma is now worth
$ 38.29
Resulting in a loss of
$ 61.71 (61.71%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.03 (-2.39%)
Day High
$1.42
Day Low
$1.33
Day Open
$1.39
Prev Close
$1.42
Volume
68,390
1W Return
-1.35%
1M Return
-3.41%
3M Return
-9.41%
6M Return
-16.00%
1Y Return
-49.78%
Fundamentals
Market Cap ($ Mn)
73
PE Ratio
-
PB Ratio
9.04
PEG Ratio
-
ROE
-
ROCE
114.26%
EPS (TTM)
-
Investment Returns
1 Week
-1.35%
1 Month
-3.41%
3 Months
-9.41%
6 Months
-16.00%
9 Months
-28.92%
Financials
Quarterly
All values in $ Mn
No data available.
Updates
8Sep
OKYO Pharma to present at Cantor Global Healthcare Conference
OKYO Pharma to hold fireside chat at Cantor Global Healthcare Conference on Sept 10. FDA Type D meeting validated regulatory path for urcosimod. Annual report filing indicates strengthened cash position. Phase 3 trial for NCP treatment planned for second half of year.
2mo ago
28Jul
OKYO Pharma CSO Raj Patil buys 3,363 shares on NASDAQ
Raj Patil, Chief Scientific Officer of OKYO Pharma Limited, bought 3,363 ordinary shares on NASDAQ at $1.49 each. His total stake now stands at 20,030 shares. The move highlights internal confidence in the company's clinical-stage therapies for eye diseases.
3mo ago
27Jul
OKYO Pharma to present at BTIG Biotechnology Conference 2026
OKYO Pharma Limited will present at the virtual BTIG Biotechnology Conference 2026 on July 28-29. CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli will participate. The company is preparing to launch a Phase 3 trial for urcosimod in NCP later this year.
3mo ago
23Jul
OKYO Pharma CEO buys 15,000 shares at $1.54
OKYO Pharma Limited CEO Robert J. Dempsey purchased 15,000 ordinary shares on NASDAQ at $1.54 per share, increasing his stake. This follows recent insider purchases by the Chairman and CMO. The company is advancing its pipeline with a planned Phase 3 trial for neuropathic corneal pain.
3mo ago
20Jul
OKYO Pharma reports $20.6 million cash to fund Phase 3 trial
OKYO Pharma Limited filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026, reporting $20.6 million in cash and cash equivalents. The company raised approximately $25 million during the year, including a $22 million public offering in February 2026, to fully fund the global Phase 3 NEPTUNE trial for urcosimod. The trial, scheduled to begin in the second half of 2026, will enroll approximately 111 patients across the US and Europe.
3mo ago
13Jul
HC Wainwright maintains Buy on OKYO Pharma, cuts target to $5
HC Wainwright & Co. analyst Yi Chen maintains a Buy rating on OKYO Pharma but lowers the price target from $7 to $5, reflecting a revised valuation outlook.
